Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: The Not-As-Bad-As-Expected Opera Of Johnson & Johnson’s Q2 Earnings

What Do J&J’s Bellwether Results Tell Us About Wider Pharma Sector In 2020?

Executive Summary

With something for everyone in Johnson & Johnson’s second-quarter earnings report, a nudge upwards for full-year guidance could not disguise the jump down from January’s pre-pandemic expectations.

You may also be interested in...



J&J Bullish On Procedure Recovery As Q2 Device Sales Beat Analyst Expectations

Johnson & Johnson management said they expect medical device sales to make a quick recovery in the third and fourth quarter of 2020 after seeing a faster-than-expected reuptake of procedures during the second quarter.

J&J Accelerates COVID-19 Vaccine Development, Targeting Phase III Start In September

Phase I/IIa trial is poised to start in July versus a prior target of September, with a Phase III start targeted for late September. J&J also reported 2.1% pharma sales growth, reflecting an impact from COVID-19.

Stock Watch: AstraZeneca’s Third-Quarter Crescendo

In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel